Navigation Links
Molecule Uses Cellular Recycling to Treat Kidney Cancer
Date:7/7/2008

Finding represents a major shift for targeted therapy, study says

MONDAY, July 7 (HealthDay News) -- A molecule that uses a cellular recycling process called autophagy to kill cancer cells has been identified by Stanford University researchers.

Autophagy is normally used by cells to conserve resources during times of stress.

"Increasing evidence implicates a role for autophagy in cancer, but it is not well understood how cellular and environmental cues drive authophagic cells down survival or death pathways," study senior author Dr. Amato J. Giaccia said in a prepared statement.

In this study, Giaccia and his colleagues focused on renal cell carcinoma (RCC), the most common form of kidney cancer. In most cases, RCC is caused by a mutation of the von Hippel-Lindau (VHL) tumor suppressor gene and often fails to respond to treatment.

"Since RCCs have a poor prognosis and are refractory to standard chemotherapy, there is a need to develop new therapies for kidney cancer," Giaccia said.

The researchers searched for molecules that could destroy VHL-deficient kidney cancer and identified a molecule called STF-62247, which enhanced autophagy in VHL-deficient cells. The molecule didn't affect cells with normal VHL.

"We have found a small molecule that selectively induces cell death in VHL-deficient cells, such as those that are found in kidney cancer. This represents a paradigm shift for targeted therapy," Giaccia said.

The study was to be published in the July 8 issue of the journal Cancer Cell.

More information

The American Cancer Society has more about kidney cancer.



-- Robert Preidt



SOURCE: Cell Press, news release, July 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New class of RNA molecules may be important in human cancer
2. Molecule Promising Against Huntingtons Disease
3. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
4. Vulnerability to Stress Linked to Brain Molecule
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. Study Describes Molecules That Control Blood Pressure
7. Researchers identify molecules with interesting anti-clotting properties
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
10. Major Advance in the Observation of DNA Molecules
11. Molecules can block breast cancers ability to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... and aural rehabilitation—provided by audiologists—to remain a critical part of public access to ... Drug Administration (FDA) announced this week that, starting immediately, it would ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: